The safety of adenoviral agents has been validated by more than fifty years of human employ. The highly characterized biology of the virus has allowed rational molecular engineering for improved functionalities. The un-paralleled up-scalability of adenovirus is fully commensurate with pharmacologic development. In the aggregate, these considerations underscore the unique potentials of adenovirus for the widest range of gene therapy and vaccine applications. Our break-through vectorology is fully unique within the gene therapy space and creates exceptional opportunities within this burgeoning sector.
Precision’s Unique Vector Capacities Drive Development of Gene Therapy Agents for Inherited Genetic Disorders
Precision’s Unique Vector Capacities Drive Development of Vaccine Agents for Emerging Disease Vaccination